Raymond James Trust N.A. Has $13.26 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Raymond James Trust N.A. raised its position in Pfizer Inc. (NYSE:PFE) by 3.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 458,248 shares of the biopharmaceutical company’s stock after acquiring an additional 16,827 shares during the period. Raymond James Trust N.A.’s holdings in Pfizer were worth $13,262,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the second quarter worth $29,000. Gladius Capital Management LP raised its position in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP bought a new position in Pfizer during the 2nd quarter valued at $31,000. Finally, Financial Connections Group Inc. purchased a new position in Pfizer during the 2nd quarter worth $34,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.5 %

Shares of Pfizer stock opened at $25.06 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $142.03 billion, a P/E ratio of 33.87, a P/E/G ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock’s 50-day simple moving average is $28.28 and its 200 day simple moving average is $28.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the company earned ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.